AG
URGN icon

Advisor Group’s UroGen Pharma URGN Stock Holding History

Advisor Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-133
Closed -$6K – 5333
2018
Q4 		$6K Sell
133
-37
-22% -$1.66K ﹤0.01% 4452
2018
Q3 		$8K Sell
170
-37
-18% -$1.72K ﹤0.01% 4403
2018
Q2 		$10K Buy
+207
New +$12K ﹤0.01% 4085

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group's URGN Position: Q1 2019 in Review

Advisor Group sold out of UroGen Pharma (URGN) in Q1 2019, closing a stake of 133 shares — an estimated $6K sold.

Advisor Group first reported a position in URGN in Q2 2018 and held it in 3 quarters. The position peaked at $10K in Q2 2018. 74 funds tracked by Wall St. Rank hold URGN as of Q1 2019.

  • Advisor Group reported no remaining UroGen Pharma position as of Q1 2019 after selling out during the quarter.
  • Advisor Group sold 133 UroGen Pharma shares in Q1 2019, an estimated $6K.
  • Advisor Group first reported a position in UroGen Pharma in Q2 2018 and held it in 3 quarters.
  • Advisor Group's UroGen Pharma position peaked at $10K in Q2 2018.
  • 74 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2019.

Based on Advisor Group's 13F filing for Q1 2019, filed 9 May 2019.